NIH Nominates Scientific Management Review Board
Members
National Institutes of Health (NIH) Director Elias A. Zerhouni,
M.D., has nominated individuals to serve as members of the Scientific
Management Review Board (SMRB). The SMRB will examine the NIH's
organizational structure and balance and will provide recommendations
for enhancing the agency's mission through greater agency flexibility
and responsiveness.
SMRB was authorized by the NIH Reform Act of 2006 and signed into
law by the President in January 2007. This act was the first omnibus
reauthorization of NIH in 14 years. A major element of the Reform
Act of 2006 was the new authority it gave to the NIH Director to
improve program coordination, assemble and analyze accurate data,
implement strategic plans based on institute and center determined
priorities, ensure resources are properly allocated, and further
maximize investigator-initiated research in high impact and emerging
research areas.
"My charge to the Board is to be thorough with their organizational
reviews," said NIH Director Elias A. Zerhouni, M.D. "NIH
must respond nimbly and strategically in an era when the scale
and complexity of the scientific and health problems we are facing
require constant innovation and adaptability due to the rapidly
changing pace of promising discoveries and increased interdisciplinary
efforts."
More information about the NIH reform Act of 2006 can be found
at: http://www.nih.gov/about/reauthorization/index.htm
Norman R. Augustine has been nominated to serve as the board's
first chairman. Mr. Augustine is the former chairman of the executive
committee of Lockheed Martin Corporation. He received his B.S.
and M.S. degrees from Princeton University, majoring in aeronautical
engineering. Mr. Augustine was a consultant to the Executive Office
of the President, Assistant Secretary of the Army for Research
and Development, and was Undersecretary of the Army. After leaving
government service, he served as vice president for operations,
Martin Marietta Aerospace Corporation, president, Martin Marietta
Denver Aerospace Company, and president and chief operating officer. He
was also chairman, advisory board Department of Aeromechanical
Engineering, Princeton University and professor, Mechanical and
Aerospace Engineering Department, Princeton University. Mr.
Augustine served as the president of Martin Marietta Aerospace
Corporation between 1986 and 1987. He also served as the CEO of
Martin Marietta from 1987 and as chairman of Martin Marietta from
1988. He is the chair of the audit committee of the National Association
of Corporate Directors.
Additional nominees to the SMRB Board are:
Jeremy Berg, Ph.D., director, National Institute of General Medical
Sciences
William R. Brody, M.D., Ph.D., president, Johns Hopkins University
Gail Cassell, Ph.D., vice president, Scientific Affairs and Distinguished
Lilly Research Scholar for Infectious Diseases, Eli Lilly
Anthony Fauci, M.D., director, National Institute of Allergy and
Infectious Diseases
Dan Goldin, former NASA administrator
Richard Hodes, M.D., director, National Institute on Aging
Stephen Katz, M.D., director, National Institute of Arthritis and
Musculoskeletal and Skin Diseases
Thomas Kelly, M.D., Ph.D., director, Sloan-Kettering Institute,
Memorial Sloan-Kettering Cancer Center
Story Landis, Ph.D., director, National Institute of Neurological
Disorders and Stroke
Elizabeth G. Nabel, M.D., director, National Heart, Lung, and Blood
Institute
John E. Niederhuber, M.D., director, National Cancer Institute
Deborah Powell, M.D., dean and assistant vice president for clinical
science, University of Minnesota Medical School
Griffin Rodgers, M.D., director, National Institute of Diabetes
and Digestive and Kidney Diseases
William Roper, M.D., dean of the School of Medicine and CEO of
Health Care System, University of North Carolina
Arthur Rubenstein, M.D., executive vice president, University of
Pennsylvania for the Health System; dean, University of Pennsylvania
School of Medicine
Solomon H. Snyder, M.D., professor of psychiatry, Neurosciences
and Pharmacology, Johns Hopkins University
Lawrence Tabak, D.D.S., Ph.D., director, National Institute of
Dental and Craniofacial Research
Harold Varmus, M.D., president, Memorial Sloan-Kettering Cancer
Center
Eugene Washington, M.D., Executive Vice Chancellor and Provost, University of California, San Francisco
Huda Zoghbi, M.D., professor, HHMI Investigator, Baylor College
of Medicine
The Office of the Director, the central office at NIH, is responsible
for setting policy for NIH, which includes 27 Institutes and Centers.
This involves planning, managing, and coordinating the programs
and activities of all NIH components. The Office of the Director
also includes program offices which are responsible for stimulating
specific areas of research throughout NIH. Additional information
is available at http://www.nih.gov/icd/od/.
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and Centers
and is a component of the U.S. Department of Health and Human Services.
It is the primary federal agency for conducting and supporting basic,
clinical and translational medical research, and it investigates
the causes, treatments, and cures for both common and rare diseases.
For more information about NIH and its programs, visit www.nih.gov. |